Search Results - "Proia, David A."

HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models by Whitesell, Luke, Santagata, Sandro, Mendillo, Marc L., Lin, Nancy U., Proia, David A., Lindquist, Susan

“…The efficacy of hormonal therapies for advanced estrogen receptorpositive breast cancers is limited by the nearly inevitable development of acquired…”
Get full text

Mitochondrial electron transport is the cellular target of the oncology drug elesclomol by Blackman, Ronald K, Cheung-Ong, Kahlin, Gebbia, Marinella, Proia, David A, He, Suqin, Kepros, Jane, Jonneaux, Aurelie, Marchetti, Philippe, Kluza, Jerome, Rao, Patricia E, Wada, Yumiko, Giaever, Guri, Nislow, Corey

“…Elesclomol is a first-in-class investigational drug currently undergoing clinical evaluation as a novel cancer therapeutic. The potent antitumor activity of…”
Get full text

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy by Ying, Weiwen, Du, Zhenjian, Sun, Lijun, Foley, Kevin P, Proia, David A, Blackman, Ronald K, Zhou, Dan, Inoue, Takayo, Tatsuta, Noriaki, Sang, Jim, Ye, Shuxia, Acquaviva, Jamie, Ogawa, Luisa Shin, Wada, Yumiko, Barsoum, James, Koya, Keizo

“…Targeted inhibition of the molecular chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an…”
Get full text

Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy by Proia, David A, Kaufmann, Gunnar F

“…The demonstration that immune checkpoint blockade can meaningfully improve outcomes for cancer patients has revolutionized the field of immuno-oncology. New…”
Get more information

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer by Sang, Jim, Acquaviva, Jaime, Friedland, Julie C, Smith, Donald L, Sequeira, Manuel, Zhang, Chaohua, Jiang, Qin, Xue, Liquan, Lovly, Christine M, Jimenez, John-Paul, Shaw, Alice T, Doebele, Robert C, He, Suqin, Bates, Richard C, Camidge, D Ross, Morris, Stephan W, El-Hariry, Iman, Proia, David A

“…EML4-ALK gene rearrangements define a unique subset of patients with non-small cell lung carcinoma (NSCLC), and the clinical success of the anaplastic lymphoma…”
Get more information

Reconstruction of human mammary tissues in a mouse model by Kuperwasser, Charlotte, Proia, David A

“…Establishing a model system that more accurately recapitulates both normal and neoplastic breast epithelial development in rodents is central to studying human…”
Get full text

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer by He, Suqin, Smith, Donald L., Sequeira, Manuel, Sang, Jim, Bates, Richard C., Proia, David A.

“…Summary The integration of targeted agents to standard cytotoxic regimens has improved outcomes for patients with colorectal cancer (CRC) over recent years;…”
Get full text

Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer by Beck, Tim N., Korobeynikov, Vladislav A., Kudinov, Alexander E., Georgopoulos, Rachel, Solanki, Nehal R., Andrews-Hoke, Magda, Kistner, Timothy M., Pépin, David, Donahoe, Patricia K., Nicolas, Emmanuelle, Einarson, Margret B., Zhou, Yan, Boumber, Yanis, Proia, David A., Serebriiskii, Ilya G., Golemis, Erica A.

“…Anti-Müllerian hormone (AMH) and its type II receptor AMHR2, both previously thought to primarily function in gonadal tissue, were unexpectedly identified as…”
Get full text

Ganetespib limits ciliation and cystogenesis in autosomal‐dominant polycystic kidney disease (ADPKD) by Nikonova, Anna S., Deneka, Alexander Y., Kiseleva, Anna A., Korobeynikov, Vladislav, Gaponova, Anna, Serebriiskii, Ilya G., Kopp, Meghan C., Hensley, Harvey H., Seeger‐Nukpezah, Tamina N., Somlo, Stefan, Proia, David A., Golemis, Erica A.

“…Autosomal‐dominant polycystic kidney disease (ADPKD) is associated with progressive formation of renal cysts, kidney enlargement, hypertension, and typically…”
Get full text

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism by Acquaviva, Jaime, He, Suqin, Zhang, Chaohua, Jimenez, John-Paul, Nagai, Masazumi, Sang, Jim, Sequeira, Manuel, Smith, Donald L, Ogawa, Luisa Shin, Inoue, Takayo, Tatsuta, Noriaki, Knowles, Margaret A, Bates, Richard C, Proia, David A

“…Activating mutations and/or overexpression of FGFR3 are common in bladder cancer, making FGFR3 an attractive therapeutic target in this disease. In addition,…”
Get full text

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors by London, Cheryl A, Acquaviva, Jaime, Smith, Donald L, Sequeira, Manuel, Ogawa, Luisa Shin, Gardner, Heather L, Bernabe, Louis Feo, Bear, Misty D, Bechtel, Sandra A, Proia, David A

“…STA-1474, prodrug of the heat shock protein 90 inhibitor (HSP90i) ganetespib, previously demonstrated activity in canine preclinical models of cancer;…”
Get full text

mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis by Acquaviva, Jaime, He, Suqin, Sang, Jim, Smith, Donald L, Sequeira, Manuel, Zhang, Chaohua, Bates, Richard C, Proia, David A

“…Because of their pleiotropic effects on critical oncoproteins, inhibitors of HSP90 represent a promising new class of therapeutic agents for the treatment of…”
Get full text

Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease by Seeger-Nukpezah, Tamina, Proia, David A., Egleston, Brian L., Nikonova, Anna S., Kent, Tatiana, Cai, Kathy Q., Hensley, Harvey H., Ying, Weiwen, Chimmanamada, Dinesh, Serebriiskii, Ilya G., Golemis, Erica A.

“…Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic syndrome with an incidence of 1:500 in the population, arising from inherited…”
Get full text

Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling by Proia, David A, Foley, Kevin P, Korbut, Tim, Sang, Jim, Smith, Don, Bates, Richard C, Liu, Yuan, Rosenberg, Alex F, Zhou, Dan, Koya, Keizo, Barsoum, James, Blackman, Ronald K

“…There is accumulating evidence that dysregulated JAK signaling occurs in a wide variety of cancer types. In particular, mutations in JAK2 can result in the…”
Get full text

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression by HE, SUQIN, ZHANG, CHAOHUA, SHAFI, AYESHA A, SEQUEIRA, MANUEL, ACQUAVIVA, JAIME, FRIEDLAND, JULIE C, SANG, JIM, SMITH, DONALD L, WEIGEL, NANCY L, WADA, YUMIKO, PROIA, DAVID A

“…Androgen ablation therapy represents the first line of therapeutic intervention in men with advanced or recurrent prostate tumors. However, the incomplete…”
Get full text

Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice by Smithline, Zachary B, Nikonova, Anna S, Hensley, Harvey H, Cai, Kathy Q, Egleston, Brian L, Proia, David A, Seeger-Nukpezah, Tamina, Golemis, Erica A

“…Polycystic liver disease (PLD) occurs in 75-90% of patients affected by autosomal dominant polycystic kidney disease (ADPKD), which affects 1∶400-1,000 adults…”
Get full text

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise by PROIA, David A, BATES, Richard C

“…As with many physiologic processes that become subverted during tumorigenesis, the chaperoning activity of heat shock protein 90 (HSP90) is often exploited by…”
Get full text

Stroma: Tumor Agonist or Antagonist by Proia, David A., Kuperwasser, Charlotte

“…Extensive research has been conducted over several decades understanding the genetic changes that occur in normal cells to promote them towards a transformed…”
Get full text

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib by Acquaviva, Jaime, Smith, Donald L, Jimenez, John-Paul, Zhang, Chaohua, Sequeira, Manuel, He, Suqin, Sang, Jim, Bates, Richard C, Proia, David A

“…Activating BRAF kinase mutations serve as oncogenic drivers in over half of all melanomas, a feature that has been exploited in the development of new…”
Get full text

Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib by Acquaviva, Jaime, Smith, Donald L, Sang, Jim, Friedland, Julie C, He, Suqin, Sequeira, Manuel, Zhang, Chaohua, Wada, Yumiko, Proia, David A

“…Mutant KRAS is a feature of more than 25% of non-small cell lung cancers (NSCLC) and represents one of the most prevalent oncogenic drivers in this disease…”
Get full text